Uracil/tegafur plus cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a multi-institutional phase II trial

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Yukito IchinoseH Niitani

Abstract

To evaluate the efficacy and toxicity of a novel combination treatment using concurrent radiotherapy with cisplatin plus UFT, which is comprised of uracil and tegafur, in locally advanced non-small cell lung cancer (NSCLC) patients. In this Phase II trial, patients with unresectable stage III NSCLC were treated with the oral administration of UFT (400 mg/m(2)/d tegafur) on days 1-14 and days 29-42 whereas 80 mg/m(2) cisplatin was administered i.v. on days 8 and 36. Radiotherapy, with a total dose of 60 Gy, was delivered in 30 fractions from day 1. Seventy patients were enrolled and eligible, as follows: 57 males/13 females; mean age 61 ranging from 36 to 74; performance status 0/1:45/25; stage IIIA/IIIB, 14/56. A complete response was observed in two patients and a partial response in 54 patients, and the overall response rate was 81% (95% confidence interval; 70-89%). The median survival, the 1- and 2-year survival rates were 16.5 months, 67% and 33%, respectively. Grade 3/4 leukopenia occurred in 14%/1% of the patients. Grades 3 non-hematological toxicities were only reported in three patients with nausea, two with esophagitis and one with pneumonitis whereas no grade 4 non-hematological toxicity was observed. UFT plus cispla...Continue Reading

References

Feb 20, 1992·The New England Journal of Medicine·C Schaake-KoningA Nijs
Dec 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W HeimD Alt
Nov 1, 1982·International Journal of Radiation Oncology, Biology, Physics·J E ByfieldF Kulhanian
Mar 1, 1982·International Journal of Radiation Oncology, Biology, Physics·E B Douple, R C Richmond
Jan 1, 1981·Cancer·A B MillerA Winkler
Oct 19, 1999·International Journal of Radiation Oncology, Biology, Physics·A de la TorreG Aragón
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K FuruseY Ariyoshi
Oct 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P M HoffR Pazdur
Feb 13, 2001·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·J SaitoT Nakabayashi
Jan 11, 2002·The New England Journal of Medicine·Joan H SchillerUNKNOWN Eastern Cooperative Oncology Group
Aug 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathy S AlbainRobert B Livingston
May 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David R GandaraUNKNOWN Southwest Oncology Group

❮ Previous
Next ❯

Citations

Jul 26, 2013·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Kazuyuki TsujinoMasahiko Ando
Nov 5, 2011·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Yukito IchinoseMasahiro Fukuoka
Sep 4, 2013·The Annals of Thoracic Surgery·Masafumi YamaguchiYukito Ichinose
May 7, 2013·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Shunichi SugawaraUNKNOWN North Japan Lung Cancer Study Group
Oct 22, 2008·International Journal of Radiation Oncology, Biology, Physics·Kyoichi KairaMasatomo Mori

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.